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Use of the Term “Antley-Bixler Syndrome”:
Minimizing Confusion
To the Editor:
We read with great interest the publication by Huang et
al. (2005), which made a number of significant contribu-
tions to our understanding of the biochemistry and mo-
lecular genetics of a newly described, highly variable, au-
tosomal recessive condition referred to as “cytochrome
P450 oxidoreductase (POR [MIM 124015]) deficiency.”
We agree with the authors that what has been termed
“Antley-Bixler syndrome” (ABS [MIM 207410]) in the
scientific literature is genetically heterogeneous with at
least two distinct disorders, (1) ABS without disordered
steroidogenesis, which appears to be a variant of the
autosomal dominant fibroblast growth factor receptor
(FGFR)–related craniosynostosis syndromes, and (2) ABS
with disordered steroidogenesis, which appears to be
caused by severe mutations in POR. However, we dis-
agree with the authors’ proposition “that the term ‘ABS’
be reserved for those patients with the skeletal dysmor-
phologic findings initially reported by Antley and Bixler
(1975) but who have normal genitalia and normal ste-
roidogenesis, and that patients with the skeletal dys-
morphologic phenotype plus evidence of disordered ste-
roidogenesis be referred to as having ‘POR deficiency’”
(Huang et al. 2005, p. 745).
Although the female patient first described by Antley
and Bixler did not have ambiguous genitalia or any re-
ported steroid anomalies, there are a number of reasons
why these facts do not provide sufficient justification to
reserve the term “ABS” for patients with FGFR muta-
tions. These include:
1. To our knowledge, the patient described by Antley
and Bixler (1975) has not had molecular testing for
mutations in FGFR2 or POR. Therefore, POR de-
ficiency cannot be ruled out for this patient.
2. Steroid abnormalities associated with POR defi-
ciency and ABS are not always recognized without
the use of urinary steroid profiling (Shackleton et
al. 2004). In fact, Huang et al. (2005) found POR
mutations in both alleles of two female patients with
ABS who were initially believed not to have steroid
abnormalities when first reported by Reardon et al.
(2000).
3. The presence of ambiguous genitalia is not neces-
sary for making a diagnosis of POR deficiency. This
is illustrated by the two females with ABS and nor-
mal genitalia who are reported by Huang et al.
(2005) to have mutations in POR. In addition, we
have published a family with classic ABS in which
a male child had ambiguous genitalia but his sister
did not (Cragun et al. 2004). Both children had
evidence of abnormal steroid metabolism, and mu-
tations in POR have subsequently been confirmed.
Because of similarities with respect to phenotype, mo-
lecular findings, and pattern of inheritance, patients with
FGFR mutations should be grouped with those with the
other autosomal dominant FGFR-related craniosynosto-
sis syndromes. This proposal is supported by others who
have questioned the diagnosis of ABS for a patient who
has FGFR2 mutations (Gorlin 1999; Gripp et al. 1999).
Even Huang et al. (2005) admit that the diagnosis of ABS
was reconsidered in some of the patients they report with
FGFR mutations.
Clarifying which individuals represent classic ABS has
been difficult because few pictures of patients with ABS
and known POR or FGFR mutations have been pub-
lished, and the clinical descriptions of these patients of-
ten lack detail. However, some subtle features—includ-
ing a pear-shaped or bulbous nose, low-set and dysplas-
tic ears, arachnodactyly, and/or rockerbottom feet—are
often present in patients with ABS who are known or
suspected to have POR deficiency; these features are not
described in patients with known FGFR mutations. In-
terestingly, the patient reported by Antley and Bixler
(1975) had a bulbous nose, low-set dysplastic ears, and
arachnodactyly. In addition, that patient also had sig-
nificant camptodactyly, which is described in patients
who likely have POR deficiency more commonly than
in those with FGFR mutations. Compared with cases of
ABS that are suspected or known to be caused by POR
deficiency, patients with FGFR mutations generally have
more-severe proptosis and facial dysmorphism that is
more similar to that of patients with Pfeiffer syndrome
or Crouzon syndrome (two FGFR-related craniosynos-
tosis syndromes). On the basis of this evidence, the au-
thors’ conclusion—that “aside from the genital anoma-
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lies attributable to disordered steroidogenesis, no mor-
phologic feature distinguished patients with POR mu-
tations from those with FGFR mutations” (Huang et al.
2005, p. 736)—may not be warranted.
Continuing to use the term “ABS” for patients with
FGFR mutations will only contribute to the confusion
that is already present in the literature. The concern is
that this confusion may interfere with proper patient man-
agement and counseling, both of which depend on the
ability of clinicians and researchers to clearly recognize,
understand, and convey to patients the differences be-
tween POR deficiency and FGFR-related craniosynosto-
sis syndromes.
Use of the term “ABS” to describe patients with POR
deficiency who are at the more severe end of the pheno-
typic spectrum can be clinically useful in distinguishing
them from patients with POR deficiency who have mild
or no skeletal defects (Arlt et al. 2004; Flu¨ck et al. 2004;
Fukami et al. 2004). We believe it would be better to
reserve the use of the term “ABS” for patients with POR
deficiency and clinically significant craniosynostosis and/
or radiohumoral synostosis.
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“Antley-Bixler Syndrome”—A Reply to Cragun
and Hopkin
To the Editor:
Cragun and Hopkin (2005 [in this issue]) raise a series
of points concerning use of the term “Antley-Bixler syn-
drome” (ABS), both in our recent paper in this journal
(Huang et al. 2005) and elsewhere. We agree that it is
useful to minimize confusion: the best way to do this may
be to discard the term “ABS” and other eponymic terms
once the molecular genetics and cell biology of a disease
have been worked out. However, until such eponyms are
discarded, as stated in our paper, “we propose that the
term ‘ABS’ be reserved for those patients with the skeletal
dysmorphologic findings initially reported by Antley and
Bixler (1975) but who have normal genitalia and normal
steroidogenesis” (Huang et al. 2005, p. 745). Cragun
and Hopkin suggest that “patients with FGFR mutations
should be grouped with those with other autosomal domi-
nant FGFR-related craniosynostosis syndromes.” We
